University of Texas Texas AM Investment Management Co. Buys Shares of 95 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

University of Texas Texas AM Investment Management Co. bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the first quarter, Holdings Channel reports. The fund bought 95 shares of the pharmaceutical company’s stock, valued at approximately $46,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of VRTX. Brighton Jones LLC grew its position in shares of Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after buying an additional 579 shares during the last quarter. Orion Portfolio Solutions LLC grew its position in shares of Vertex Pharmaceuticals by 1.7% in the 4th quarter. Orion Portfolio Solutions LLC now owns 8,963 shares of the pharmaceutical company’s stock worth $3,609,000 after buying an additional 154 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in shares of Vertex Pharmaceuticals by 14.7% in the 4th quarter. Brown Brothers Harriman & Co. now owns 2,842 shares of the pharmaceutical company’s stock worth $1,144,000 after buying an additional 364 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $3,731,000. Finally, RWA Wealth Partners LLC grew its position in shares of Vertex Pharmaceuticals by 2.7% in the 4th quarter. RWA Wealth Partners LLC now owns 3,583 shares of the pharmaceutical company’s stock worth $1,443,000 after buying an additional 95 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on VRTX shares. Morgan Stanley cut their price objective on shares of Vertex Pharmaceuticals from $464.00 to $460.00 and set an “equal weight” rating on the stock in a research report on Friday, June 20th. HC Wainwright reissued a “buy” rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. The Goldman Sachs Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $512.30.

Vertex Pharmaceuticals Stock Down 1.9%

VRTX stock opened at $460.83 on Tuesday. The firm’s fifty day simple moving average is $453.53 and its 200-day simple moving average is $465.77. The company has a market capitalization of $118.34 billion, a P/E ratio of -117.56 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.85 billion. During the same period last year, the company posted $4.76 earnings per share. The business’s quarterly revenue was up 2.6% on a year-over-year basis. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.